ELECTROCONVULSIVE SHOCK EFFECTS ON BRAIN RECEPTORS
电休克对脑感受器的影响
基本信息
- 批准号:3380663
- 负责人:
- 金额:$ 12.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-07-01 至 1991-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The overall objectives of this research are to compare the
effects of administration of electroconvulsive shock (ECS) and
antidepressant drugs on serotonergic and noradrenergic
receptors in rat brain. In particular, the following
hypotheses will be tested: 1) that ECS differs from most
antidepressant drug treatments in its effects on 5-HT-2
receptors, and 2) that ECS differs from most antidepressant
drug treatments in its effects on up-regulated beta-adrenergic
receptors. To test the latter hypothesis, we will use a new
model in which following highly specific lesions of 5-HT
neurons or inhibition of 5-HT synthesis, beta-adrenergic
receptors are markedly increased in brain. Among the specific
aims of this research are: 1) To determine the effects of ECS
and antidepressant drugs on the increased number of
beta-adrenergic receptors by measuring ligand binding and
isoproterenol-stimulated cyclic AMP production in brain. 2) To
use quantitative autoradiography to identify and compare the
specific brain regions in which beta-adrenergic receptors are
decreased by ECS and antidepressant drugs, and to identify the
beta receptor subtype affected by these treatments. 3) To
identify by quantitative autoradiography the specific regions
and layers of cerebral cortex in which 5-HT-2 receptors are
increased by ECS and decreased by antidepressant drugs. 4) To
compare the effects of ECS and antidepressant drugs on 5-HT-2
and alpha-1-adrenergic receptor-mediated phosphoinositide
hydrolysis. 5) To determine whether lesions of norepinephrine
axons alter the effects of ECS or antidepressant drugs on
5-HT-2 receptors.
These studies should provide new information about the effects
of ECS and antidepressant drugs on the receptor systems for the
two neurotransmitters that have been most often implicated in
depression and its treatment. This information should
contribute to an eventual understanding of the neurochemical
effects of ECS and antidepressant drugs and potentially to the
rationale for the clinical effects of electroconvulsive therapy.
这项研究的总体目标是比较
电惊厥性休克(ECS)给药的效果
抗抑郁药物对5-羟色胺能和去甲肾上腺素能的影响
大鼠大脑中的受体。特别是,以下内容
将检验假设:1)ECS与MOST不同
抗抑郁药物治疗对5-羟色胺-2的影响
受体,以及2)ECS与大多数抗抑郁药不同
药物治疗对上调β-肾上腺素能的影响
感受器。为了检验后一种假设,我们将使用一个新的
5-羟色胺高度特异性损伤后的模型
神经元或抑制5-羟色胺合成,β-肾上腺素能
大脑中的受体显著增加。在具体的
本研究的目的是:1)确定ECS的效果
而抗抑郁药物的数量增加了
通过测定配基结合和β-肾上腺素能受体
异丙肾上腺素刺激脑内环磷酸腺苷的产生。2)至
使用定量放射自显影来识别和比较
β-肾上腺素能受体所在的特定脑区
被ECS和抗抑郁药物降低,并确定
β受体亚型受这些处理的影响。3)至
用定量放射自显影识别特定区域
以及大脑皮层中5-羟色胺-2受体的层
ECS升高,抗抑郁药降低。4)至
体外循环与抗抑郁药对5-羟色胺-2的影响比较
和α-1-肾上腺素能受体介导的肌醇磷脂
水解液。5)确定去甲肾上腺素的损害是否
轴突改变ECS或抗抑郁药物对
5-HT-2受体。
这些研究应该会提供有关影响的新信息。
ECS和抗抑郁药物在受体系统上的作用
两种神经递质最常被牵连到
抑郁症及其治疗。此信息应为
有助于对神经化学物质的最终理解
ECS和抗抑郁药物的影响以及对潜在的
电休克治疗临床效果的理论基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH J KELLAR其他文献
KENNETH J KELLAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH J KELLAR', 18)}}的其他基金
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8223233 - 财政年份:2010
- 资助金额:
$ 12.8万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8616367 - 财政年份:2010
- 资助金额:
$ 12.8万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8038405 - 财政年份:2010
- 资助金额:
$ 12.8万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
7779037 - 财政年份:2010
- 资助金额:
$ 12.8万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8435485 - 财政年份:2010
- 资助金额:
$ 12.8万 - 项目类别:
NICOTINIC RECEPTORS AUTONOMIC GANGLIA AND ADRENAL GLAND
烟碱受体自主神经节和肾上腺
- 批准号:
6489471 - 财政年份:2001
- 资助金额:
$ 12.8万 - 项目类别:
Pharmacology and Regulation of Nicotinic Receptor Subtypes
烟碱受体亚型的药理学和调节
- 批准号:
8491947 - 财政年份:2001
- 资助金额:
$ 12.8万 - 项目类别:
NICOTINIC RECEPTORS AUTONOMIC GANGLIA AND ADRENAL GLAND
烟碱受体自主神经节和肾上腺
- 批准号:
6700834 - 财政年份:2001
- 资助金额:
$ 12.8万 - 项目类别:
NICOTINIC RECEPTORS AUTONOMIC GANGLIA AND ADRENAL GLAND
烟碱受体自主神经节和肾上腺
- 批准号:
6841602 - 财政年份:2001
- 资助金额:
$ 12.8万 - 项目类别:
相似海外基金
Stratification of depression based on lysophospholipid metabolic disorders and innovative development of novel antidepressants
基于溶血磷脂代谢紊乱的抑郁症分层及新型抗抑郁药的创新开发
- 批准号:
23H02839 - 财政年份:2023
- 资助金额:
$ 12.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The role of antidepressants in central and peripheral myeloid HIV persistence and inflammation
抗抑郁药在中枢和外周髓系 HIV 持续存在和炎症中的作用
- 批准号:
10762810 - 财政年份:2023
- 资助金额:
$ 12.8万 - 项目类别:
Concomitant use of antidepressants and oral antidiabetic drugs and the risk of hypoglycemia
抗抑郁药和口服抗糖尿病药的同时使用和低血糖的风险
- 批准号:
10679095 - 财政年份:2022
- 资助金额:
$ 12.8万 - 项目类别:
Concomitant use of antidepressants and oral antidiabetic drugs and the risk of hypoglycemia
抗抑郁药和口服抗糖尿病药的同时使用和低血糖的风险
- 批准号:
10526807 - 财政年份:2022
- 资助金额:
$ 12.8万 - 项目类别:
Leveraging Rapid-Acting Antidepressants for Personalized Response
利用速效抗抑郁药进行个性化治疗
- 批准号:
10387133 - 财政年份:2021
- 资助金额:
$ 12.8万 - 项目类别:
Leveraging Rapid-Acting Antidepressants for Personalized Response
利用速效抗抑郁药进行个性化治疗
- 批准号:
10490846 - 财政年份:2021
- 资助金额:
$ 12.8万 - 项目类别:
Leveraging Rapid-Acting Antidepressants for Personalized Response
利用速效抗抑郁药进行个性化反应
- 批准号:
10687872 - 财政年份:2021
- 资助金额:
$ 12.8万 - 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:
10569044 - 财政年份:2020
- 资助金额:
$ 12.8万 - 项目类别:
Do antidepressants promote the wound healing of the diabetes?
抗抑郁药能促进糖尿病伤口愈合吗?
- 批准号:
20K09860 - 财政年份:2020
- 资助金额:
$ 12.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:
10117285 - 财政年份:2020
- 资助金额:
$ 12.8万 - 项目类别: